Furthermore, tumor cells within the bone microenvironment interfere with key ligand‐receptor interactions (NKR/NKR‐L and TRAIL/DR4) and activate TAM tyrosine kinase receptors, which collectively impair NK cell antitumor activity [55, 56]. This evidence concerns the gene NTRK1 and neoplasm.